A compound having the structure: wherein R 1, R 2, R 3, R 4, and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1, R 2, R 3, R 4, or R 5 are other than H; R 6 is H, or halogen; and B has the structure: wherein n is an integer from 0-1; α, β, χ, δ, ε, and φ are each independently absent or present, and when present each is a bond; Z 1 is N; Z 2 is N or NR 7; wherein R 7 is H, C 1 -C 4 alkyl, or oxetane; X is C or N; Y 1, Y 2, Y 3, and Y 4 are each independently CR 8, CH 2, N, or N-R 9, wherein R 8 is H, halogen, OCH 3, CN, or CF 3; and R 9 is H, CN, oxetane, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, (C 1 -C 4 alkyl)(C 3 -C 6 cycloalkyl), (C 1 -C 6 alkyl)-OCH 3, (C 1 -C 6 alkyl)-CF 3, C -(C 1 -C 6 alkyl), C 2 -(C 1 -C 6 alkyl), C -NH 2, C NH-(C 1 -C 6 alkyl), C -(C 6 aryl), C -(C 6 heteroaryl), C -pyrrolidine, C -piperidine, C -piperazine, (C 1 -C 6 alkyl)-CO 2 H, (C 1 -C 6 alkyl)-CO 2 (C 1 -C 6 alkyl) or SO 2 -(C 1 -C 6 alkyl), wherein when R 1 is CF 3, R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3, R 3 is H, R 4 is CF 3, and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3, R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof. R 1, R 2, R 3, R 4, and R 5 are each independently H, halogen, CF 3 or C 1 -C 4 alkyl, wherein two or more of R 1, R 2, R 3, R 4, or R 5 are other than H; R 6 is H, or halogen; and B has the structure: wherein n is an integer from 0-1; α, β, χ, δ, ε, and φ are each independently absent or present, and when present each is a bond; Z 1 is N; Z 2 is N or NR 7; wherein R 7 is H, C 1 -C 4 alkyl, or oxetane; X is C or N; Y 1, Y 2, Y 3, and Y 4 are each independently CR 8, CH 2, N, or N-R 9, wherein R 8 is H, halogen, OCH 3, CN, or CF 3; and R 9 is H, CN, oxetane, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, (C 1 -C 4 alkyl)(C 3 -C 6 cycloalkyl), (C 1 -C 6 alkyl)-OCH 3, (C 1 -C 6 alkyl)-CF 3, C -(C 1 -C 6 alkyl), C 2 -(C 1 -C 6 alkyl), C -NH 2, C NH-(C 1 -C 6 alkyl), C -(C 6 aryl), C -(C 6 heteroaryl), C -pyrrolidine, C -piperidine, C -piperazine, (C 1 -C 6 alkyl)-CO 2 H, (C 1 -C 6 alkyl)-CO 2 (C 1 -C 6 alkyl) or SO 2 -(C 1 -C 6 alkyl), n is an integer from 0-1; α, β, χ, δ, ε, and φ are each independently absent or present, and when present each is a bond; Z 1 is N; Z 2 is N or NR 7; wherein R 7 is H, C 1 -C 4 alkyl, or oxetane; X is C or N; Y 1, Y 2, Y 3, and Y 4 are each independently CR 8, CH 2, N, or N-R 9, wherein R 8 is H, halogen, OCH 3, CN, or CF 3; and R 9 is H, CN, oxetane, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, (C 1 -C 4 alkyl)(C 3 -C 6 cycloalkyl), (C 1 -C 6 alkyl)-OCH 3, (C 1 -C 6 alkyl)-CF 3, C -(C 1 -C 6 alkyl), C 2 -(C 1 -C 6 alkyl), C -NH 2, C NH-(C 1 -C 6 alkyl), C -(C 6 aryl), C -(C 6 heteroaryl), C -pyrrolidine, C -piperidine, C -piperazine, (C 1 -C 6 alkyl)-CO 2 H, (C 1 -C 6 alkyl)-CO 2 (C 1 -C 6 alkyl) or SO 2 -(C 1 -C 6 alkyl), wherein when R 1 is CF 3, R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is H, R 2 is CF 3, R 3 is H, R 4 is CF 3, and R 5 is H, or R 1 is Cl, R 2 is H, R 3 is H, R 4 is F, and R 5 is H, or R 1 is CF 3, R 2 is H, R 3 is F, R 4 is H, and R 5 is H, or R 1 is CF 3, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, or R 1 is Cl, R 2 is F, R 3 is H, R 4 is H, and R 5 is H, then B is other than or a pharmaceutically acceptable salt thereof.